Fidelity Management & Research Co… recently announced the acquisition of new stake in FibroGen Inc. (NASDAQ:FGEN). The institutional investor has increased its shareholding in the Healthcare company by 3.25% to 9.59 million shares with purchase of 0.3 million shares. This fresh investment now brings its stake to 10.76% valued currently at $320.56 million. In addition, The Vanguard Group, Inc. raised its holdings by 36403.0 to 6.91 million shares. And PRIMECAP Management Co. has lifted its position by 381.37% or 3.98 million shares – to 5.02 million shares.
With over 0.44 million FibroGen Inc. (FGEN) shares trading Monday and a closing price of $43.13 on the day, the dollar volume was approximately $18.76 million. The shares have shown a positive weekly performance of 6.76% and its price on 07/06/20 lost nearly -0.85%. Currently, there are 88.22M common shares owned by the public and among those 81.73M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: Several analysts who have offered their price forecasts for FGEN have a consensus price objective of $59.25. The analysts have set the share’s price value over the next 12 months at a high of $80.00 and a low of $40.00 should the stock experience a downside. Incidentally, analysts’ outlook for the FibroGen Inc. stock is 2.00 for the next 12 months. The average price target is 27.21% above its last price level and an upside to the estimated low will see the stock lose -7.83% over that period. But an upside of 46.09% will see the stock hit the forecast high price target while mean target price for the stock is $61.00.
Insiders at the company have transacted a total of 159 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 65 of these insider trades were purchases, accounting for 696,668 shares. Insider sales of the common stock occurred on 94 occasions, with total insider shares sold totaling 499,821 shares.
The top 3 mutual fund holders in FibroGen Inc. are PRIMECAP Odyssey Aggressive Growt, Vanguard Total Stock Market Index, and Vanguard Small Cap Index Fund. PRIMECAP Odyssey Aggressive Growt owns 2.34 million shares of the company’s stock, all valued at over $78.26 million. The company bought an additional 2.03 million shares recently to bring their total holdings to about 2.63% of the shares outstanding. Vanguard Total Stock Market Index sold 12885.0 shares to see its total holdings shrink to 2.14 million shares valued at over $71.67 million and representing 2.40% of the shares outstanding. Vanguard Small Cap Index Fund sold 15675.0 shares to bring its total holdings to over 1.92 million shares at a value of $64.25 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.16% of the shares outstanding.
Shares of FibroGen Inc. (NASDAQ: FGEN) opened at $44.00, up $0.5 from a prior closing price of $43.50. However, the script later closed the day at $43.13, down -0.85%. The company’s stock has a 5-day price change of 6.76% and 32.42% over the past three months. FGEN shares are trading 0.56% year to date (YTD), with the 12-month market performance down to -2.71% lower. It has a 12-month low price of $22.65 and touched a high of $48.95 over the same period. Currently, 0.44 million shares have been traded, compared to an average intraday trading volume of 734.28K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.32%, 14.30%, and 9.82% respectively.
Institutional ownership of FibroGen Inc. (NASDAQ: FGEN) shares accounts for 73.50% of the company’s 88.22M shares outstanding. Mutual fund holders own 25.28%, while other institutional holders and individual stakeholders account for 47.67% and 15.22% respectively.
It has a market capitalization of $3.72B and a beta (3y monthly) value of 1.58. The stock’s earnings-per-share (ttm) stands at -$1.32. The company has a Quick Ratio of 11.00 with the debt-to-equity ratio at 0.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.33% over the week and 5.07% over the month.
Analysts forecast that FibroGen Inc. (FGEN) will achieve an EPS of -$0.32 for the current quarter, -$0.72 for the next quarter and -$1.03 for 2021. The lowest estimate earnings-per-share for the quarter is -$1.07 while analysts give the company a high EPS estimate of $0.73. Comparatively, EPS for the current quarter was $1.26 a year ago. Earnings per share for the fiscal year are expected to increase by 13.60%, and 23.10% over the next financial year. EPS over the next five years should compared to 22.50% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate FibroGen Inc. (FGEN) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 4 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the FGEN, a number of firms have released research notes about the stock. Cowen stated their Market Perform rating for the stock in a research note on May 01, 2020, with the firm’s price target at $40. BofA/Merrill coverage for the FibroGen Inc. (FGEN) stock in a research note released on April 27, 2020 offered a Neutral rating with a price target of $45. Goldman was of a view on May 29, 2019 that the stock is Neutral, while William Blair gave the stock Mkt Perform rating on May 10, 2019 . Piper Jaffray on their part issued Neutral rating on April 12, 2019.